{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T04:44:36Z","timestamp":1780461876974,"version":"3.54.1"},"update-to":[{"DOI":"10.1002\/14651858.cd007779","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2010,10,6]],"date-time":"2010-10-06T00:00:00Z","timestamp":1286323200000}}],"reference-count":72,"publisher":"Wiley","issue":"2","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd007779.pub2","type":"journal-article","created":{"date-parts":[[2010,9,28]],"date-time":"2010-09-28T15:31:32Z","timestamp":1285687892000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Levomepromazine for schizophrenia"],"prefix":"10.1002","volume":"2013","author":[{"given":"Parthipan","family":"Sivaraman","sequence":"first","affiliation":[{"name":"Sheffield Health and Social Care Foundation NHS Trust; East Glade Centre; Sheffield South Yorkshire UK S12 4QN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranganath D","family":"Rattehalli","sequence":"additional","affiliation":[{"name":"Assertive Outreach Team; 22 The Auenue York UK YO30 6AS"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahesh B","family":"Jayaram","sequence":"additional","affiliation":[{"name":"Leeds Partnership Foundation NHS Trust; CMHT; Aire Court Lingwell Grove Leeds UK LS10 4BS"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,10,6]]},"reference":[{"key":"10.1002\/14651858.CD007779.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1055\/s-0028-1094312","article-title":"Ergebnisse eines Doppelblindversuches von HF 1854 (8-Chlor-11-(4 methyl-1-piperazinyl)-5H-dibenzo (b,e) (1,4) diazepin) im Vergleich zu Levomepromazin","volume":"4","author":"Angst","year":"1971","journal-title":"Pharmakopsychiatrie und Neuropsychopharmakologie"},{"key":"10.1002\/14651858.CD007779.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1192\/bjp.104.436.855","article-title":"Assessing a new phenothiazine","volume":"104","author":"Baker","year":"1958","journal-title":"Journal of Mental Science"},{"issue":"1","key":"10.1002\/14651858.CD007779.pub2-BIB0004|cit3","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/00004714-199602000-00007","article-title":"Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients","volume":"16","author":"Blin","year":"1996","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD007779.pub2-BIB0005|cit4","first-page":"189","article-title":"Anxiolytic profiles of levomepromazine, haloperidol and risperidone in 62 schizophrenic patients","volume":"51","author":"Blin","year":"1992","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD007779.pub2-BIB0006|cit5","first-page":"31","article-title":"Anxiolytic profiles of levomepromazine, haloperidol, and risperidone in 62 schizophrenic patients","volume":"106","author":"Blin","year":"1992","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD007779.pub2-BIB0007|cit6","first-page":"388","article-title":"Comparison of anxiolytic properties of levomepromazine, haloperidol and risperidone in schizophrenic patients","volume":"29","author":"Blin","year":"1991","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD007779.pub2-BIB0003|cit7","unstructured":"Blin O Azorin JM Bouhours P Fondarai J Anxiolytic profiles of risperidone, haloperidol, and levomepromazine in schizophrenia: a factorial and regression analysis 9th World Congress of Psychiatry; 1993 Jun 6-12; Rio de Janeiro, Brazil France 1993 24"},{"issue":"Suppl 1. Pt B","key":"10.1002\/14651858.CD007779.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"169B","DOI":"10.1097\/00002826-199202001-00326","article-title":"Comparison of risperidone, haloperidol and levomepromazine in schizophrenia: a factorial analysis and discriminant function analysis","volume":"15","author":"Blin","year":"1992","journal-title":"Clinical Neuropharmacology"},{"key":"10.1002\/14651858.CD007779.pub2-BIB0009|cit9","unstructured":"Tatossian A Comparitive double-blind trial of the efficacy of risperidone, haloperidol and levomepromazine (methotrimeprazine) in patients with an acute exacerbation of schizophrenia presenting psychotic anxiety symptoms Clinical report 1991"},{"issue":"4","key":"10.1002\/14651858.CD007779.pub2-BIB0010|cit10","first-page":"271","article-title":"Levomepromazine versus chlorpromazine in treatment-resistant schizophrenia: a double-blind randomized trial","volume":"31","author":"Lal","year":"2006","journal-title":"Journal of psychiatry & neuroscience : JPN"},{"issue":"1","key":"10.1002\/14651858.CD007779.pub2-BIB0011|cit11","first-page":"1","article-title":"Current status of pharmacotherapy in schizophrenia","volume":"20","author":"Akimoto","year":"1966","journal-title":"Folia Psychiatrica et Neurologica Japonica"},{"issue":"3","key":"10.1002\/14651858.CD007779.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/j.1525-1594.1983.tb04207.x","article-title":"Levomepromazine elimination in patients during active and sham hemodialysis","volume":"7","author":"Andersson","year":"1983","journal-title":"Artificial Organs"},{"issue":"23","key":"10.1002\/14651858.CD007779.pub2-BIB0013|cit13","first-page":"1095","article-title":"Therapy of acute schizophrenic attacks. High dosage haloperidol therapy compared with a two component treatment","volume":"97","author":"Blaha","year":"1979","journal-title":"Fortschritte der Medizin"},{"issue":"19","key":"10.1002\/14651858.CD007779.pub2-BIB0014|cit14","first-page":"615","article-title":"Retrospective and prospective studies on the clinical effect of clopenthixol (sordinol) in endogenous phychoses","volume":"97","author":"Hicklin","year":"1967","journal-title":"Schweizerische Medizinische Wochenschrift"},{"issue":"6","key":"10.1002\/14651858.CD007779.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.eurpsy.2004.07.001","article-title":"Combined therapy with low-potency neuroleptic levomepromazine as an adjunct to haloperidol for agitated patients with acute exacerbation of schizophrenia","volume":"19","author":"Higashima","year":"2004","journal-title":"European Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD007779.pub2-BIB0016|cit16","first-page":"168","article-title":"The effect of quetiapine on different domains of cognition and negative symptoms in schizophrenia","volume":"67","author":"Horacek","year":"2004","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD007779.pub2-BIB0017|cit17","unstructured":"Horacek J Seifertova D Janu L Petranova T The effect of quetiapine on different domains of cognition and negative symptoms in schizophrenia 12th Biennial Winter Workshop on Schizophrenia; 2004 Feb 7-13, Davos, Switzerland 2004"},{"issue":"5","key":"10.1002\/14651858.CD007779.pub2-BIB0018|cit18","first-page":"745","article-title":"The place of insulin coma therapy among modern methods of treatment of paroxysmal schizophrenia patients","volume":"86","author":"Kalinin","year":"1986","journal-title":"Zhurnal Nevropatologii i Psikhiatrii imeni S.S. Korsakova"},{"issue":"10","key":"10.1002\/14651858.CD007779.pub2-BIB0019|cit19","first-page":"1293","article-title":"Comparison of clinical effects of etizolam, nitrazepam and levomepromazine on schizophrenic sleep disturbance using double-blind technique","volume":"12","author":"Kojima","year":"1983","journal-title":"Seishin Igaku (Clinical Psychiatry)"},{"key":"10.1002\/14651858.CD007779.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1192\/bjp.106.444.1093","article-title":"A clinical trial of four tranquillizing drugs","volume":"106","author":"Leitch","year":"1960","journal-title":"Journal of Mental Science"},{"issue":"1","key":"10.1002\/14651858.CD007779.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0920-9964(00)90822-3","article-title":"Agitation in acute episode of schizophrenia: carbamazepine treatment in combination with haloperidol versus combined neuroleptics","volume":"41","author":"Makaric","year":"2000","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD007779.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1192\/bjp.106.444.1105","article-title":"A clinical trial of largactil (chlorpromazine), stemeticl (prochlorperazine) and veractil (methotrimeprazine)","volume":"106","author":"Milne","year":"1960","journal-title":"Journal of Mental Science"},{"key":"10.1002\/14651858.CD007779.pub2-BIB0023|cit23","unstructured":"Moller HJ Incidence of EPS under risperidone therapy 1st International Risperidone Investigators' Meeting; 1992 Mar 9-10; Paris, France 1992 32"},{"key":"10.1002\/14651858.CD007779.pub2-BIB0024|cit24","unstructured":"Moller HJ Incidence of EPS under risperidone therapy 1st International Risperidone Investigators' Meeting; 1992 Mar 9-10; Paris, France 1992 32"},{"issue":"2","key":"10.1002\/14651858.CD007779.pub2-BIB0025|cit25","first-page":"104","article-title":"Outline classification of neuroleptic drugs based on results of short-term control crossed studies in schizophrenia","volume":"72","author":"Nahunek","year":"1976","journal-title":"Ceskoslovenska Psychiatrie"},{"issue":"1","key":"10.1002\/14651858.CD007779.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1055\/s-2005-837766","article-title":"Switching female schizophrenic patients to quetiapine from conventional antipsychotic drugs: Effects on hyperprolactinemia","volume":"38","author":"Nakajima","year":"2005","journal-title":"Pharmacopsychiatry"},{"key":"10.1002\/14651858.CD007779.pub2-BIB0027|cit27","unstructured":"Pancheri P Risperidone: efficacy on affective and mood-related symptoms 1st International Risperidone Investigators' Meeting; 1992 Mar 9-10; Paris, France 1992 30 1"},{"issue":"10","key":"10.1002\/14651858.CD007779.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1176\/ajp.128.10.1207","article-title":"The use of methyldopa in schizophrenia: a review and comparative study","volume":"128","author":"Pecknold","year":"1972","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD007779.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1192\/bjp.106.442.160","article-title":"A comparative controlled trial of methotrimeprazine ('veractil') in chronic schizophrenia","volume":"106","author":"Quinn","year":"1960","journal-title":"Journal of Mental Science"},{"issue":"2","key":"10.1002\/14651858.CD007779.pub2-BIB0030|cit30","first-page":"187","article-title":"Experimental studies on the dream reports of psychotic, neurotic and normal subjects: Ego functions and the influence of neuroleptics","volume":"131","author":"Schnetzler","year":"1973","journal-title":"Annales Medico-Psychologiques"},{"issue":"3","key":"10.1002\/14651858.CD007779.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1017\/S1461145706006651","article-title":"Association of the dopamine receptor interacting protein gene, NEF3, with early response to antipsychotic medication","volume":"10","author":"Strous","year":"2007","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD007779.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/00007691-199706000-00003","article-title":"Increased plasma concentrations of bromperidol and its reduced metabolite with levomepromazine, but not with thioridazine","volume":"19","author":"Suzuki","year":"1997","journal-title":"Therapeutic Drug Monitoring"},{"issue":"2","key":"10.1002\/14651858.CD007779.pub2-BIB0033|cit33","first-page":"315","article-title":"Differences in therapeutic effects of phenothiazine drugs","volume":"9","author":"Vinar","year":"1968","journal-title":"Agressologie"},{"issue":"3","key":"10.1002\/14651858.CD007779.pub2-BIB0034|cit34","first-page":"176","article-title":"Schizophrenic syndromes improving without neuroleptic drug treatment","volume":"72","author":"Vinar","year":"1976","journal-title":"Ceskoslovenska Psychiatrie"},{"issue":"10","key":"10.1002\/14651858.CD007779.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/archpsyc.63.10.1079","article-title":"Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1)","volume":"63","author":"Jones","year":"2006","journal-title":"Archives of General Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD007779.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1017\/S1121189X00002281","article-title":"Do findings from new trials for schizophrenia fit with existing evidence: not duped...just beguiled?","volume":"16","author":"Adams","year":"2007","journal-title":"Epidemiologia e Psichiatria Sociale"},{"key":"10.1002\/14651858.CD007779.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/bmj.313.7066.1200","article-title":"Detecting skewness from summary information","volume":"313","author":"Altman","year":"1996","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD007779.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1136\/bmj.4.5726.18","article-title":"Correlation of Subjective Side Effects with PlasmaConcentrations of Nortriptyline","volume":"4","author":"Marie","year":"1970","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD007779.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.1996.03540080059030","article-title":"Improving the quality of randomized controlled trials. The CONSORT statement","volume":"276","author":"Begg","year":"1996","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD007779.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/bmj.315.7108.600","article-title":"Statistics notes-trials randomised in clusters","volume":"315","author":"Bland","year":"1997","journal-title":"BMJ"},{"issue":"6","key":"10.1002\/14651858.CD007779.pub2-BIB0041|cit41","first-page":"543","article-title":"The Psychotic Anxiety Scale (PAS). Evaluation of inter-rater reliability and correspondence factorial analysis","volume":"15","author":"Blin","year":"1989 Nov-Dec","journal-title":"Encephale"},{"key":"10.1002\/14651858.CD007779.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1056\/NEJM199403103301006","article-title":"Schizophrenia","volume":"330","author":"Carpenter","year":"1994","journal-title":"New England Journal of Medicine"},{"issue":"12","key":"10.1002\/14651858.CD007779.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD007779.pub2-BIB0044|cit44","first-page":"233","article-title":"The extrapyramidal Symptom Rating Scale","volume":"7","author":"Chouinard","year":"1980","journal-title":"Can J Neurol Sci"},{"key":"10.1002\/14651858.CD007779.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/archpsyc.63.10.1079","article-title":"Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: cost utility of the latest antipsychotic drugs in schizophrenia study (CUTLASS 1)","volume":"63","author":"Jones","year":"2006","journal-title":"Archives of General Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD007779.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/cpt1976194435","article-title":"Pharmacokinetics of levomepromazine after single and multiple doses","volume":"19","author":"Dahl","year":"1976","journal-title":"Clinical Pharmacology and Therapeutics\u00a0"},{"key":"10.1002\/14651858.CD007779.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/00007691-198204000-00012","article-title":"Plasma and erythrocyte levels of levomepromazine and two of its nonpolar metabolites in psychiatric patients","volume":"4","author":"Dahl","year":"1982","journal-title":"Therapeutic Drug Monitoring"},{"key":"10.1002\/14651858.CD007779.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1001\/archpsyc.60.6.553","article-title":"A meta-analysis of the efficacy of second-generation antipsychotics","volume":"60","author":"Davis","year":"2003","journal-title":"Archives of General Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD007779.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/BF02599201","article-title":"The unit of analysis error in studies about physicians' patient care behavior","volume":"7","author":"Divine","year":"1992","journal-title":"Journal of General Internal Medicine"},{"key":"10.1002\/14651858.CD007779.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1002\/sim.1301","article-title":"Issues in the meta-analysis of cluster randomized trials","volume":"21","author":"Donner","year":"2002","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD007779.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"13","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD007779.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"key":"10.1002\/14651858.CD007779.pub2-BIB0053|cit53","doi-asserted-by":"crossref","unstructured":"Sproston K Nazroo J Ethnic minority psychiatric illness rates in the community (EMPIRIC) - Quantitative report Department of Health -UK 2002","DOI":"10.1037\/e623492007-001"},{"issue":"9618","key":"10.1002\/14651858.CD007779.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(08)60486-9","article-title":"The European First Episode Schizophrenia Trial (EUFEST)","volume":"371","author":"Kahn","year":"2008","journal-title":"The Lancet"},{"key":"10.1002\/14651858.CD007779.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1136\/bmj.321.7273.1371","article-title":"Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis","volume":"321","author":"Geddes","year":"2000","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD007779.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/oxfordjournals.aje.a009904","article-title":"Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the health survey for England","volume":"149","author":"Gulliford","year":"1994","journal-title":"American Journal of Epidemiology"},{"key":"10.1002\/14651858.CD007779.pub2-BIB0057|cit57","doi-asserted-by":"crossref","unstructured":"Guy W Clinical global impressions ECDEU assessment manual for psychopharmacology, revised. Rockville (MD): US National Institute of Health, Psychopharmacology Research Branch 1976 217 222","DOI":"10.1037\/e591322011-001"},{"key":"10.1002\/14651858.CD007779.pub2-BIB0058|cit58","doi-asserted-by":"crossref","unstructured":"Guy W Abnormal involuntary movement scales ECDEU assessment manual for psychopharmacology, revised. Rockville (MD): US National Institute of Health, Psychopharmacology Research Branch 1976 534 537","DOI":"10.1037\/e591322011-001"},{"issue":"1","key":"10.1002\/14651858.CD007779.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/BF03192290","article-title":"Metabolism of levomepromazine in man","volume":"20","author":"Hals","year":"1995","journal-title":"European Journal of Drug Metabolism and Pharmacokinetics"},{"issue":"7414","key":"10.1002\/14651858.CD007779.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD007779.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/9780470712184.ch8","article-title":"Chapter 8: Assessing risk of bias in included studies","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions 5.0.1[updated September 2008]","author":"Higgins","year":"2008"},{"key":"10.1002\/14651858.CD007779.pub2-BIB0062|cit62","first-page":"612","article-title":"Course and outcome of schizophrenia and their prediction","volume-title":"Oxford Textbook of Psychiatry","volume":"1","author":"Gelder","year":"2000"},{"key":"10.1002\/14651858.CD007779.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1136\/bmj.323.7303.42","article-title":"Systematic reviews in health care: Assessing the quality of controlled clinical trials","volume":"323","author":"J\u00fcni","year":"2001","journal-title":"British Medical Journal"},{"issue":"9","key":"10.1002\/14651858.CD007779.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","article-title":"Clozapine for treatment resistant schizophrenia: a double-blind comparison with chlorpromazine","volume":"45","author":"Kane","year":"1988","journal-title":"Arch General Psychiatry"},{"key":"10.1002\/14651858.CD007779.pub2-BIB0065|cit65","doi-asserted-by":"crossref","unstructured":"Kay SR Opler LA Fiszbein A Positive and negative syndrome scale (PANSS) Rating manual. San Rafael (CA): Social and Behavioural Science Documents 1987","DOI":"10.1093\/schbul\/13.2.261"},{"issue":"6","key":"10.1002\/14651858.CD007779.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/j.1600-0447.1993.tb03391.x","article-title":"Levomepromazine receptor binding profile in human brain - implications for treatment-resistant schizophrenia","volume":"87","author":"Lal","year":"1993","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"11","key":"10.1002\/14651858.CD007779.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/S0006-3223(01)01303-8","article-title":"The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches","volume":"50","author":"Lieberman","year":"2001","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD007779.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1192\/bjp.176.3.249","article-title":"Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia","volume":"176","author":"Marshall","year":"2000","journal-title":"British Journal of Psychiatry"},{"issue":"285","key":"10.1002\/14651858.CD007779.pub2-BIB0069|cit69","first-page":"91","article-title":"The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials","volume":"1987","author":"Moher","year":"2001","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD007779.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The Brief Psychiatric Rating Scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychological Reports"},{"issue":"5","key":"10.1002\/14651858.CD007779.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta3050","article-title":"Methods for evaluating area-wide and organisation-based intervention in health and health care a systematic review","volume":"3","author":"Ukoumunne","year":"1999","journal-title":"Health Technology Assessment"},{"key":"10.1002\/14651858.CD007779.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.schres.2007.12.319","article-title":"The Leeds Outcomes Stakeholders Survey (LOSS) Study","volume":"3","author":"Xia","year":"2008","journal-title":"Schizophrenia research"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD007779.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T03:24:23Z","timestamp":1740540263000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD007779.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Schizophrenia Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2010,10,6]]},"references-count":72,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2013,2]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd007779.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,10,6]]}}}